Navigation Links
Quest PharmaTech Receives Support from National Research Council's Industrial Research Assistance Program (NRC-IRAP) to develop Ultrasound Technology for the Treatment of Cancer
Date:4/22/2008

EDMONTON, April 22 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. ("Quest" or the "Company") is pleased to announce that it will receive generous support from NRC-IRAP towards the development of Quest's Sonodynamic Therapy (SDT) for oncology applications.

Sonodynamic Therapy arises out of the Company's long-term interest in Hypocrellin-based photodynamic therapy for oncology and skin diseases. The Company's lead compound, SL017, with Intense Pulse Light is currently being evaluated for hair removal applications in a 90 patient Phase II clinical trial. A second product, SL052, in combination with laser light activation is in late-stage pre-clinical development for prostate cancer treatment and is scheduled to enter a Phase I clinical trial during the second half of 2008. Both products can also be activated by ultrasound.

SDT involves the administration of non-toxic pharmaceutical agents which may be activated deep within the body, by ultrasound, which is in itself non-toxic. The attractive features of this technology for cancer treatment emerges from the ability to focus the ultrasound energy on malignancy sites buried deep in tissues and to locally activate a preloaded sonosensitizer. The goal of SDT is to provide effective and specific eradication or control of tumors, while minimizing or eliminating toxicity and morbidity to the remainder of the patient.

Financial support of up to $198,362 from NRC/IRAP will help the Company to obtain proof-of-concept for the use of its proprietary Hypocrellin-based compounds for Sonodynamic Therapy applications. Technology development will also include new formulations involving nanoparticles and development of unique ultrasound transducers. In addition to the financial support, IRAP will continue to play an advisory role in acquiring complementary technologies to commercialize SDT-based products. The overall program will be coordinated by Dr. Gerald Miller, Executive Consultant to the Company and form
'/>"/>

SOURCE Quest PharmaTech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
2. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
3. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
4. VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
5. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
6. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
7. VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
8. Sinovac Requests Extension for Annual Shareholders Meeting
9. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
10. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
11. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... October 22, 2014 Grace Century, a ... healthcare projects, announces the addition of Dr. Yousef ... its advisory team. Dr. Siddiqui will provide further healthcare ... A graduate of University College Medical School ... in medicine in 2001. With further certification as a ...
(Date:10/22/2014)... According to new market research report ... Integration, Deployment & Support), by Service Model (SaaS, ... Others (Hybrid & Community)) - Global Forecast to ... Cloud Professional Services Market into various sub-segments with ... also identifies the drivers and restraints for this ...
(Date:10/22/2014)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... Oral Amphotericin B program.  The company recently announced ... work involving samples from HIV/AIDS patients exposed to ... clinical studies and regulatory filings to move forward ... approximately $700,000 of funding and technological advice from ...
(Date:10/22/2014)... DUBLIN , Oct. 22, 2014 ... "Organic Electronics Market by Material, by Application, Geography ... report to their offering. Organic electronics, ... a branch of material science which deals with small ... as organic because small molecules and polymers are carbon ...
Breaking Biology Technology:Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3
... OLIGOMERIX, Inc. today announced the receipt of a ... $323,000 from the National Institute on Aging of the ... program is to develop novel biomarker assays for Alzheimer,s ... apolipoprotein E (apoE) proteins will be monitored in cerebrospinal ...
... FRANCISCO, Feb. 25 VIA Pharmaceuticals, Inc. (Nasdaq: ... development of compounds for the treatment of cardiovascular and ... Patent No. 7,495,024 entitled "Phenylalkyl N-Hydroxyureas for Combating Atherosclerotic ... for the treatment of atherosclerosis. This patent is ...
... /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq:, SSRX ), ... manufacturing and marketing biopharmaceutical products, today,announced that it ... and,full year ended December 31, 2008 after the ... Following the earnings announcement, ...
Cached Biology Technology:OLIGOMERIX Awarded NIH Grant to Develop Novel Biomarkers for Alzheimer's Disease 2VIA Pharmaceuticals Announces Grant of New Patent on Lead Compound VIA-2291 2VIA Pharmaceuticals Announces Grant of New Patent on Lead Compound VIA-2291 3VIA Pharmaceuticals Announces Grant of New Patent on Lead Compound VIA-2291 43SBio Inc. to Report 2008 Fourth Quarter and Full Year Earnings on March 11, 2009 2
(Date:10/18/2014)... sample of patients with undiagnosed, suspected genetic conditions, a ... a higher molecular diagnostic yield than traditional molecular diagnostic ... . The study is being released to coincide with ... Exome sequencing, which sequences the protein­coding region of the ... present in a cell or organism), has been rapidly ...
(Date:10/17/2014)... . Why do ... to reproduce? And why are there two sexes anyway? These ... of the research journal Molecular Human Reproduction published ... Bielefeld University Bielefeld has compiled this special issue on sperm ... to copulate with several males in quick succession – chimpanzees ...
(Date:10/17/2014)... German . To ... treating overdoses, doctors are often limited to supportive therapy such ... a combination of drugs involved. So what can be done ... pills? ETH professor Jean-Christophe Leroux from the Institute of Pharmaceutical ... this question. "The task was to develop an agent that ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Sperm wars 2Emergency aid for overdoses 2Emergency aid for overdoses 3
... raise questions about why such losses matter and why ... traditionally responded to such questions by citing societal benefits ... like controlling pests and diseases, promoting the productivity of ... many others. Nevertheless, many of these presumed benefits are ...
... Battery technology hasn,t kept pace with advancements in portable ... One revolutionary concept being pursued by a team of ... capable of converting movement from humans or found in ... variable capacitor generators known as "dielectric elastomer generators" (DEGs) ...
... Rochelle, NY, April 6, 2011 The successful ... survival and reduce the risk of neurological consequences ... the premier issue of Therapeutic Hypothermia and ... published by Mary Ann Liebert, Inc. This groundbreaking ...
Cached Biology News:Precedent-setting evidence of the benefits of biodiversity 2Precedent-setting evidence of the benefits of biodiversity 3Precedent-setting evidence of the benefits of biodiversity 4Replacing batteries may become a thing of the past, thanks to 'soft generators' 2Hypothermia proven to improve survival and outcomes following out-of-hospital cardiac arrest 2Hypothermia proven to improve survival and outcomes following out-of-hospital cardiac arrest 3
... hormones which belong to the transforming ... superfamily is a large group of ... aspects of development, reproductive function and ... TGF-s, bone morphogenetic proteins, growth differentiation ...
... Antibody Plate is a 96-well ELISA-compatible ... This antibody (mouse IgG 1 ) ... glutathione-S-transferase (GST), and binds with ... fusion protein in which the tag ...
... Testing Laboratory (RTL) can provide you ... years. ,,Microbial method development and validation ... the conditions of your GMP manufacturing ... products,,We offer a full spectrum of ...
... QED Bioscience has over 23 years of ... lines. We have made antibodies to large ... and viral antigens, and plasmid DNA-encoded antigens. ... is unique, so our hybridoma development programs ...
Biology Products: